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ABSTRACT 
Alzheimer’s disease (AD), since its characterization as a precise form of dementia with its own pathological 
hallmarks, has captured scientists’ attention because of its complexity. The last 30 years have been filled with 
discoveries regarding the elusive aetiology of this disease and, thanks to advances in molecular biology and 
live imaging techniques, we now know that an important role is played by calcium (Ca2+). Ca2+, as ubiquitous 
second messenger, regulates a vast variety of cellular processes, from neuronal excitation and communication, 
to muscle fibre contraction and hormone secretion, with its action spanning a temporal scale that goes from 
microseconds to hours. It is therefore very challenging to conceive a single hypothesis that can integrate the 
numerous findings on this issue with those coming from the classical fields of AD research such as amyloid-
beta (Ab) and tau pathology. In this contribution, we will focus our attention on the Ca2+ hypothesis of AD, 
dissecting it, as much as possible, in its subcellular localization, where the Ca2+ signal meets its specificity. 
We will also follow the temporal evolution of the Ca2+ hypothesis, providing some of the most updated 
discoveries. Whenever possible, we will link the findings regarding Ca2+ dysfunction to the other players 
involved in AD pathogenesis, hoping to provide a crossover body of evidence, useful to amplify the knowledge 
that will lead towards the discovery of an effective therapy. 
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INTRODUCTION 
When the Ca2+ hypothesis of AD arose during the late '80s and early '90s, it was somehow disconnected from 
the amyloid cascade hypothesis that was already moving its first steps [1] [2]. When, later in the decade, studies 
linking Ab accumulation and deposition to Ca2+ dysregulation begun to appear the amyloid and the Ca2+ 
hypotheses became linked [3]. It was soon clear that not only amyloid plaques but also soluble Ab aggregates, 
and specifically Ab oligomers (Abo), were exerting significant toxicity, either endogenously produced or 
exogenously administered to cells and primary neurons in culture [4][5] [6] (Figure 1). The Ca2+ hypothesis 
of AD, by positing intracellular Ca2+ dysregulation as the direct consequence of Ab toxicity, offered one of the 
richest grounds for researchers in the field. It obscured the fact, however, that Ca2+ dysregulation at the onset 
of AD can occur independently of Ab accumulation and toxicity [7]. AD is now considered as a multiple hits 
disease where amyloid and tau dysfunctions are aggravated by oxidative stress, intracellular Ca2+ imbalance 
and metabolic disturbance. A large body of evidence strongly points towards Ca2+ as a possible unifying 
element underlying AD pathophysiology. According to the amyloid cascade hypothesis, Ab toxicity precedes 
tau pathology but exactly how Ab and tau cooperate in synaptic dysfunction is still a controversial issue [8]. 
Studies with AD patients as well as with amyloid precursor protein (APP) and/or tau mouse models have 
shown that tau defects affect the lateral entorhinal cortex at an early stage but require Ab to reach other cortical 
sites [9]. 
In this contribution, we will mainly focus on the relationship between cellular Ca2+ handling and AD, paying 
special attention to the crosstalk with Ab. Given the large amount of data collected, the often contrasting 
hypotheses and the vast array of cellular players more directly involved in Ca2+ homeostasis, the review will 
be divided in thematic paragraphs, based on the “anatomy” of the Ca2+ signal (Figure 2).      
 
2. PLASMA MEMBRANE CHANNELS 
It was initially suggested that Ab peptides are capable of forming plasma membrane channels [10]; indeed, 
remarkable increases in the cytosolic Ca2+ concentration ([Ca2+]cyt) were reported upon challenging cultured 
cells with either Ab40 or Ab42  [11] [12] [13]. The “ion channel hypothesis” for Ab toxicity, as proposed by 
Arispe’s group, was mainly supported by in vitro studies demonstrating the formation of cation selective 
channels, whose permeation is inhibited by metals such as Zn2+ and Cu2+ and by particular peptides designed 
to line the pore-forming region [14] [15]. The ion channel hypothesis got further support from Demuro’s 
studies showing that, in oocytes, Ab injection causes cytosolic Ca2+ rises due to Ca2+ entry across Ab channels 
formed in the plasma membrane as well as Ca2+ release via stimulation of the Gq/PLC pathway [16]. This 
hypothesis contrasts with in vivo data showing that exogenously applied Ab enhance the overall plasma 
membrane permeability to anions and cations rather than forming a Ca2+-selective pathway [17]. Since the first 
observations describing the increase in the [Ca2+]cyt of cells directly harvested from AD patients [18], many 
groups had focused their attention on this phenomenon changing the paradigm from the channel-forming to 
the channel-modulating hypothesis. This intense effort led to a plethora of hypothetical candidates capable of 
mediating cellular Ca2+ overload by Ab since neuronal cells have a vast array of Ca2+-permeable plasma 
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membrane channels at their disposal. As suggested players implicated in the pathogenesis of AD, and possibly 
mediating Ab toxicity, we will here consider the voltage-operated Ca2+ channels (VOCCs), the nicotinic 
acetylcholine receptors (nAChRs), the ionotropic glutamate receptors [N-Methyl-D-aspartate receptors 
(NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs)], the Ca2+ 
homeostasis modulator 1 (CALHM1), as well as the store-operated Ca2+ channels (SOCCs). For a thorough 
investigation on this issue, also including the plethora of Ab binding receptors, the readers should refer to 
excellent more extensive reviews of which only a few are cited here. 
 
2.1. VOCCs 
VOCCs open following membrane depolarization: the firing of an action potential by the neuron, that is the 
integrated answer of the afferent presynaptic stimuli, causes the plasma membrane to depolarize, allowing Ca2+ 
to enter from the outside along its huge electrochemical gradient. This Ca2+ signal causes the opening of a 
subtype of potassium channels that helps membrane repolarization. Ca2+ entry is coupled with synaptic vesicle 
release and intracellular signalling cascades that lead to gene transcription of several players involved in 
synapses’ maintenance and plasticity.  
VOCCs, especially those of the L-type subfamily, have long been implicated in aging and AD. Several studies 
have reported an elevated activity of these channels, with a subsequently larger Ca2+-dependent 
hyperpolarization, as a possible explanation for the deterioration of synaptic efficiency [19][20] [21] [22]. 
Given that the Ca2+ signal is spatially and temporally well defined, it is conceivable that even a little delay in 
its clearance from the cytosol after depolarization can have dramatic effects; for instance, the differential 
activation of the Ca2+-Calmodulin-dependent kinase II (CaMKII) and the phosphatase calcineurin (CN) is 
based on their different reaction times to cytosolic Ca2+ elevations [23] [24]. 
An impaired intracellular Ca2+ handling, that derives either from an increased and sustained entry through the 
membrane channels or from an inefficient clearance, can lead to an imbalance between long-term potentiation 
(LTP) and long-term depression (LTD), the electrophysiological correlates that support learning and memory, 
thus eventually resulting in disbanded memory storage. L-type ion channels are required for LTP at synapses 
between mossy fibres and CA3 pyramidal neurons. This type of LTP does not depend on NMDARs and 
involves postsynaptic Ca2+ influx carried by L-type VOCCs [25]. Patients with AD show higher L-type VOCC 
expression in the hippocampus compared with healthy individuals [26]. Forette and co-workers found that the 
blockage of L-type VOCCs with dihydropiridines, a class of drugs mainly used to treat systolic hypertension, 
was able to prevent dementia in some AD patients [27]. Consistently, in CA1 neurons of the hippocampus, 
Ca2+ currents through L-type VOCCs increase during aging in rats, together with a marked decline in learning 
and memory faculties. Chronic nimodipine treatment ameliorates memory loss, suggesting that excessive Ca2+ 
influx, through L-type Ca2+ channels, impairs learning and memory [28]. However, it has been demonstrated 
that in cultured neurons from APPsw,Lon mice, Ab suppress gene transcription that is mediated by Ca2+ influx 
(and cAMP surge) and agonists of L-type VOCCs efficiently reverse these transcriptional deficits, implicating 
a defect in Ca2+ influx rather than an augmentation [29]. Furthermore, in cell lines and primary cerebellar 
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granules from the Tg2576 AD mice, dihydropyridines, and especially the most used nimodipine, increase Ab42 
secretion through a mechanism that is independent of Ca2+ entry-blockage thus raising doubts to the possible 
therapeutic use of these compounds [30]. The effect of Ab on L-type VOCCs, whenever present, is likely dose- 
and time-dependent, since a 1-hour exposure of mouse cortical wilt-type neurons to Ab42o at submicromolar 
concentrations does not affect Ca2+ peaks and long lasting plateaus due to membrane depolarization [31]. 
Interestingly, Ab globulomers (the 48-kDa component of Abo) suppress spontaneous synaptic activity of both 
GABAergic and glutamatergic synapses by acting selectively on presynaptic P/Q type Ca2+ currents [32]. At 
the presynaptic level, Abo also affect Ca2+ influx through VOCCs, possibly explaining fast axonal transport 
defects [33].  
 
2.2. nAChRs 
Ab were reported to affect cholinergic neurons precociously. In the central nervous system, their cell bodies 
are packed in dense nuclei in the basal forebrain whilst their axonal projections spread throughout the whole 
cortex, exerting a modulatory effect rather than pure excitation. Acetylcholine binds to two families of 
receptors, the ionotropic nicotinic receptor (nAChR) and the metabotropic muscarinic one (mAChR). The first 
one is a Ca2+-permeable non-selective cation channel with a pentameric structure being formed by alpha or 
beta subunits, or a mix of the two. The subunit composition influences the pharmacological and kinetic 
properties of the channel, varying its permeability to K+, Na+ and Ca2+ [34]. 
Ionotropic nAChR exist in various forms, among which the homomeric (a7) and the heteromeric a4b2-nAChR 
were the first to be investigated in AD and they still represent the most promising targets [35] [36]. Recently 
an heteromeric a7b2 nAChR has been added to the list of Ab-binding nAChRs [37]. They differ in their Ca2+ 
permeability and sensitivity to a-bungarotoxin, and, functionally speaking, they are thought to take part in 
memory formation and attention and they have been long known to interact with Ab. In particular, several 
studies demonstrated the different affinity and exerted effects upon binding to Ab40 or Ab42 by the a7-nAChR 
and the a4b2-nAChR [38] . Summarizing, we can say that both receptor subtypes bind Ab, preferentially the 
42 amino-acid long peptides, which activate a7-nAChR in the picomolar range and inhibit it in the nanomolar 
one, whilst a4b2-nAChR binds Ab only in the nanomolar range with an inhibitory effect. Given that amyloid 
deposition is a spatially defined phenomenon, with certain brain areas exposed to premature deposition, it is 
conceivable that widely different interstitial Ab concentrations can be achieved, causing diverse effects on 
nAChRs. Albeit contrasting with regard of the Ab concentrations, species (oligomers vs monomers) and 
models used, almost all the evidence points towards a disruption of the physiologically nAChRs-driven LTP, 
which predicts an impairment in memory formation [39]. This was tested further by generating in vivo models 
bearing AD-related APP mutations in a a7-nAChR knock-out (KO) context. However, depending on the APP 
mutations employed, different results were obtained. The KO of a7-nAChR in a APPswe,Indiana mouse model 
was protected against synaptic loss and memory deficits, when tested at 13 and 16 months of age [40], while 
the same KO in a APPswe mouse model worsened both memory and Ab pathology, with increased amount of 
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soluble high molecular weight (HMW) oligomers when tested at 5 months of age [41]. To our knowledge, no 
studies were conducted to shed light on the intracellular pathway involved in these effects and, therefore, Ca2+ 
contribution is inferred only on the basis of the high Ca2+ permeability of neuronal nAChRs. Indeed, a likely 
recruitment by Ab of astrocytic a7-nAChR, altering both Ca2+ homeostasis and gliotrasmission, further 
complicates the picture [42] [43]. 
 
2.3. Ionotropic Glutamate Receptors 
A vast majority of excitatory neurons rely on glutamate as neurotransmitter and are therefore defined 
glutamatergic. Glutamate exerts its excitatory effect interacting with a diverse array of ionotropic receptors 
(NMDARs, AMPARs, KainateRs) and metabotropic receptors (mGluRs). In the AD/aging field, the best 
characterized is the NMDAR since it is pivotal in LTP. It has been proposed that the interaction of Aβo with 
NMDARs is an initiating/propagating event in the pathogenesis of AD. A high percentage of the reports 
concerning the physical and functional interactions between Aβo and NMDARs relies on synthetically 
prepared, poorly characterized oligomers, thus leading to contrasting and misleading results. Co-
immunoprecipitation with the NMDAR subunit NR1, together with genetic knockdown of the latter and 
pharmacological blockade of the whole channel had proven that Aβo preferentially target the synapses due to 
the presence of NMDARs [44] [45]. Recently, it was shown that soluble Aβ assemblies derived from the brains 
of individuals with AD interact with cellular prion protein (PrPC) to activate Fyn [46] [47]. Aβ engagement of 
PrPC-Fyn signalling requires mGluR5 as co-receptor, which leads to phosphorylation of the GluN2B subunit, 
culminating in loss of surface NMDARs and dendritic spines [48]. Furthermore, PrPC KO prevents the toxic 
effects on LTP ascribed to Aβo [48]. Nonetheless it was reported that PrPC exerts a modulatory effect on the 
glutamatergic signalling, also in physiological conditions, with neurons from a PrPC null mice exhibiting 
sustained and aberrant NMDAR mediated currents [49]; a competition between PrPC and Aβo for the 
modulation of the NMDAR activity could be present since they exert opposite effects on glycine binding at 
the co-agonist site, with PrPC negatively modulating it [50].  
It has recently been suggested that Aβo, by triggering astrocytic release of glutamate to the extrasynaptic space, 
preferentially affect extra-synaptic GluN2B-NMDARs that, at variance with synaptic GluN2A-NMDARs, 
further promote the amyloidogenic pathway and Aβ production [51]. The increased amyloid burden can 
eventually lead to neuronal toxicity by inhibition of excitatory amino acid transporters (EAATs). The 
subsequent increase in the extracellular concentration of glutamate in turn activates its receptors in an aberrant 
way; albeit never demonstrated, the interaction between Aβo and EAATs is extremely likely and there are 
studies reporting an altered expression pattern of EAATs in the AD brain [52] . Taken together, these findings 
suggest a neurotoxic action mediated by Aβo through the disbandment of the excitatory glutamatergic 
transmission. However, the only strong evidence at the in vivo level is the positive effect of the weak NMDAR 
antagonist memantine, which has long been used in AD treatment, and its successor nitro-memantine. Both 
are efficient at blocking or reversing the deleterious actions of Aβo largely because of their selectivity for 
extrasynaptic NMDARs [53] [51]. The hypothesis of Aβ toxicity involving extra-synaptic NMDARs got only 
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partial validation given that the GluN2B-NMDAR antagonist Ro 25-6981 is protective against excitotoxic 
neuronal death and Aβ-induced synapse loss in some AD mouse models [54][55], and was not confirmed in 
others [56]. 
Among other intracellular events prompted by Aβo, the activation of calcineurin and the dephosphorylation of 
NMDARs and AMPARs are primary mechanisms prompting receptor internalization [57][58][59]. Of note, 
the synaptic loss induced by Aβo through NMDAR activation seems independent of Ca2+ influx, relying mainly 
on p38-MAPK activation [60]. 
An issue of extreme importance, that has unfortunately gone almost unseen, is the fact that a substantial amount 
of data on the interaction between Aβo and glutamate receptors come from studies employing synthetic Aβo 
that have been prepared by dissolving and aging the monomers in DMEM/F12 medium [61]. The latter type 
of medium specifically causes cytosolic Ca2+ increases on its own, likely because of its high content in 
glutamate and, especially of glutamine that undergoes degradation during the aging procedure. It has been 
estimated that a 100 µM stock solution of Aβo aged in DMEM-F12 medium might contain up to 100 µM 
glutamate [62].  Using Aβo at concentrations equal or above 1 µM thus means stimulating cells with glutamate 
at concentrations sufficient to elicit Ca2+ rises through NMDA- and mGlu-Rs [62]. With this caveat, data 
interpretation is extremely complicated. Moreover, Aβo were often administered to neuronal cultures or slices, 
at concentrations considerably higher than those found in the AD brain (5-10 µM). Neuronal Ca2+ rises, due to 
addition of different culture media used for preparing Aβo, were recently described also by Caballero et al. 
[63].  The same authors show that culture media devoid of glutamate and glutamine but containing sub-
micromolar amounts of Zn2+, Cu2+, Fe2+ allow production of low molecular weight (LMW) oligomers that are 
responsible for cytosolic and mitochondria Ca2+ overload [63]. We have recently demonstrated that neither 
synthetic Ab monomers nor oligomers (ranging from low to high MW), when aged in distilled water, can elicit 
neuronal Ca2+ increases when acutely applied to neuronal cultures and PC12 cells at concentrations ranging 
from 0.5 to 5 µM (Figs 3,4) [31]. Conversely, a 1-hour exposure of cortical neurons to Aβo profoundly disturbs 
neuronal Ca2+ stores through a pathway that involves mGluR5 but not NMDARs [31]. Our findings point to a 
more subtle but insidious effect of Aβo, rather than to a massive Ca2+ load. Indeed, the idea that a long-lasting 
disease, such as AD, might act simply through the disruption of a neurotransmission as ubiquitous as the 
glutamatergic one, shed shadows on a generalized, massive involvement of neuronal glutamate receptors, and 
forces to investigate AD dysfunctions also at different levels such as the glia and the neurovascular unit 
[64][65].  
 
2.4. CALHM1 
Another relevant player in the crosstalk between Ca2+ and Ab is the Ca2+ homeostasis modulator 1 (CALHM1), 
whose polymorphism P86L was shown to segregate with early-onset forms of sporadic AD [66]. Initially 
thought to be a Ca2+-selective entry pathway and later proposed as an ATP-exiting pore majorly involved in 
taste transmission [67], CALHM1 is also more generally implicated in neuronal excitability [68]. Interestingly, 
the channel shares homology with connexins, pannexins and innexins [69]. It was also described as a relevant 
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component of neuronal ER Ca2+ leak, which is blocked by a class of compounds similar to benzodiazepines 
[70][71]. In Calhm1 knockout mice, Ab accumulation is increased by 50% because of reduced clearance by 
insulin degrading enzyme; evidence was provided showing that channel activation and Ca2+ influx are required 
for the antiamyloidogenic effect of CALHM1 [72][73].  
 
2.5. SOCCs 
All the major components (Orai and STIM proteins) of the Store-Operated Ca2+ Channels (SOCCs) have been 
described at the neuronal level and a significant amount of studies have underlined the relevance of 
Capacitative Ca2+ Entry (CCE) on the pathophysiology of the CNS [74][75][76] and AD [77][78]. 
Notwithstanding, very little is known on the effects of Aβo at this level. As originally reported by Verkhrasky 
and coll. [79], in central but not peripheral rat neurons, caffeine-sensitive Ca2+ stores are almost empty at rest, 
likely because of a highly dynamic ER Ca2+ efflux, caused by the ongoing neuronal spiking activity and 
neurotransmitter release. Despite the fact that these neurons can efficiently refill their store Ca2+ content during 
KCl-evoked depolarization, they lose the releasable Ca2+ very quickly [79]. Similarly, in mouse cortical 
neurons IP3-sensitive Ca2+ stores are very labile, and can be maximally refilled by prolonged depolarization 
[80]. On these premises it is expected that CCE, to name all the Ca2+ entry pathways linked to store depletion, 
is constitutively active at rest [81]. We have recently shown that acute treatment of mouse cortical neurons 
with Ab before the refilling process does not significantly modify the store Ca2+ content, suggesting that 
neuronal CCE is not acutely blocked by soluble Aβo [31]. We can also exclude that a 1-hour exposure to Aβo 
exerts an indirect effect on CCE given that the total store Ca2+ content is not affected, as assayed by ionomycin 
treatment [31]. Taken together, we do not envisage a direct effect of Aβo on CCE. Indeed, the opposite is 
likely true, with CCE having a direct effect on Ab secretion: a high Ca2+ influx through CCE reduces Ab 
secretion, while a low influx increases it [82]. Given the fact that FAD-linked mutant PSs reduce CCE, their 
effect on Ab accumulation is twofold: favouring Ab production as well as secretion [83]. Recently, it has been 
shown that the STIM2/neuronal SOC/CaMKII pathway is down-regulated in PS1KI mice, a condition that 
leads to loss of mushroom spines, the “stable memory spines” that are directly involved in long-term memory 
by making functionally stronger synapses [84]. The same group similarly demonstrated that, in hippocampal 
neurons of APPKI mice, mushroom spine loss results as accumulation of extracellular Ab42 [85]. The effect 
is due to overstimulation of mGluR5 by Ab42, causing ER Ca2+ overload and consequently STIM2 down-
regulation [85]. Unfortunately, the Abo employed in that study were aged in F12 medium raising doubts about 
the effective toxic agent. Of note, the ER Ca2+ overload induced by Abo, described in APPKI neurons [85], is 
a chronic and indirect effect, since different FAD-linked APP mutations modify neither the cytosolic nor the 
store Ca2+ level ([86]) but see also [87] for a reduced ER Ca2+ loading capacity in APPswe-expressing cells. 
It is worth noting that a major role for CCE is expected in astrocytes and microglia cells, whose signalling is 
largely based on ER stores. Interestingly, a reduction in Ca2+ release and sustained Ca2+ influx upon agonist 
stimulation was reported in microglia of AD patients compared to non-demented individuals [88] whereas 
chronic incubation of astrocytes with Abo at nanomolar concentrations potentiates Ca2+ influx caused by 
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activation of mGluRs [89]. 
By using plasma membrane-targeted aequorin, it was recently shown that in mouse cerebellar granules, PrPC 
exerts a tonic inhibition on SOC Entry channels by reducing the level of STIM1 phosphorylation [90].  It was 
suggested that Abo target mGluRs through the interaction with PrPC [91][48] one of the major Abo binding 
sites. Of interest, potentiation of SOCE by Abo is lost in PrPC-KO mice [90]. 
 
3. ENDOPLASMIC RETICULUM CHANNELS 
Amidst the complex scenario of ER Ca2+ dysregulation, another set of findings has shaken the scientific 
community over the past 15 years. At the beginning of the 21st century, several groups reported that presenilins 
(PS1 and PS2), the catalytic subunits of the g-secretase, are able to modify the ER Ca2+ handling when 
overexpressed in cell lines (see for reviews [83][92]). Among the most successful sets of studies was that 
produced by Bezprozvanny and co-workers, who defined the well-known paradigm of the “Ca2+ overload” 
hypothesis of AD [93]. According to this model, endogenous wild-type (wt) PSs work as the elusive ER Ca2+ 
leak channel that has puzzled scientists for decades, a function that is impaired when one PS allele bears a 
FAD-linked mutation. This situation leads to accumulation of Ca2+ inside the ER and consequently exaggerated, 
toxic release when the IP3Rs and RyRs open. This fascinating hypothesis has been questioned both by 
ourselves and other groups [94]. In fact, by using organelle-targeted Ca2+ probes, we first discovered that 
different types of PS2 mutants reduce the ER and Golgi apparatus Ca2+ content, with PS1 mutants exerting no 
effect or even partially mimicking the PS2 mutants [80][95] [7][96]. These latter exert their effects through a 
reduction of the SERCA pump with minor effects on ER Ca2+ leak [97]. By using both cytosolic and ER Ca2+ 
probes, we provided evidence that not only cell lines but also neurons in cultures and slices from PS2-N141I 
transgenic mice display a reduced store Ca2+ content and responsiveness to IP3-generating agonists, albeit in 
the presence of larger responses to ryanodine receptor (RyR) activation by caffeine [98] [99]. No clear 
differences in ER Ca2+ levels and dynamics were found between wt and PS double knockout (DKO) MEFs 
[97]. Furthermore, Foskett and coworkers similarly found no clear evidence of ER Ca2+ overload due to the 
expression of PS1 or PS2 mutants [94], and partly solved the issue demonstrating that the “apparent” Ca2+ 
overload is due to exaggerated Ca2+ release as a consequence of IP3R-gating modulation by PS mutants [100]. 
Moreover, they demonstrated that in 3xTg mice, reduction of IP3R1 expression levels attenuates Ab 
accumulation and tau hyper-phosphorylation and rescues hippocampal LTP and memory deficits [101]. In 
spite of the conflicting findings related to ER Ca2+ content and IP3R release, it might be possible to envisage 
a unifying hypothesis that sees the RyR over-expression/activation as a common pathway that brings together 
PS1 and PS2 mutants as well as Abo [102][103]. Notably, dantrolene, a RyR1 blocker used to treat malignant 
hyperthermia, has been reported to soften the symptoms and to reduce the amyloid burden in AD mouse models 
[87][104]. Since RyR is present in three different isoforms, all of them represented at the brain level, and due 
to the lack of commercially available specific antibodies, it is difficult to prove which specific isoform is 
involved. In the previous work, using quantitative PCR (qPCR), the potentiated RyR response was attributed 
to upregulation of RyR2, the isoform also linked to synaptic loss and neuronal death [105][106]. Increased 
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levels of RyR2 also characterize the mouse brain of transgenic mice based on mutant PS2 [99]. In contrast, the 
RyR3 isoform, which exerts a pro-survival effect, was not involved [107]. 
 
4. THE MITOCHONDRIA CHANNELS 
Mitochondria are currently considered among the primary targets and players in neurodegenerative diseases, 
including AD, with mitochondrial dysfunctions being considered a hallmark of Ab-induced neuronal toxicity. 
It has been shown that soluble Ab accumulate precociously in neuronal mitochondria of Tg2576 mice [108]. 
Additionally, APP has been suggested to enter the mitochondrial protein import machinery (TOM/TIM) with 
its C-terminal domain, leaving the huge N-terminal domain outside [109]. The APP intracellular domain 
(AICD) is then cleaved by mitochondrial g-secretases and dysfunctions might thus arise from P3 and Abo 
generated inside the mitochondrial matrix [110]. In vitro studies have shown that incubation of Aβo with cells 
or purified mitochondria leads to decreased mitochondrial function [111]. Others have described deleterious 
effects of Abo on the outer mitochondrial membrane (OMM) where, by activating the apoptotic BAK pore, 
they induce cytochrome c release and cell death [112]. Abo interaction with BAK on the OMM is difficult to 
conceive giving that Abo do not display a cytosolic localization, being found extracellularly, following both 
production at the plasma membrane (less than 10%) and active release, and intracellularly inside vesicles - 
endosomes and multivesicular bodies - where they are produced upon APP internalization and from which 
they cannot easily escape. Thus, under pathophysiological conditions, direct effects of Abo on intracellular 
channels (MCU, PTP, VDAC, RyR, IP3R, ER leak channels, to mention a few) are not expected, unless they 
are translocated across membranes. Whereas Ab mitochondrial localization and uptake were confirmed in 
brain human samples and in in vitro studies [108][109], mitochondrial localization of both APP and γ-secretase 
components is still waiting, leaving the topology conundrum of Aβ transfer across membranes yet an open 
question. Furthermore, it remains to be explained what physiological role APP is playing at the mitochondrial 
level. 
Among the dysfunctions through which mitochondria are likely responsible for neuronal demise in AD are 
those occurring at the ER-mitochondria network level. We discovered that upon agonist stimulation, 
mitochondria from cell lines and neurons carrying FAD-linked human PS2 mutations experience much higher 
Ca2+ transients despite a lower ER Ca2+ content. The phenomenon is due to an increased number of ER-
mitochondria close contact sites occurring at the level of mitochondria-associated ER membranes (MAMs), a 
finding reported also with PS2 but not PS1 mutants [99][113] [98][114][115]. Interestingly, Aβ can be 
produced at the MAM level and knocking down mitofusin-2 increases ER-mitochondria contact sites [116] 
and inhibits Ab production [117].   
Indirect effects on the expression level of VDAC1 and IP3R3, the corresponding ER facing IP3Rs, have also 
been reported for Aβ at nanomolar concentrations [113]. Indeed, the effect is rapid since a 1-hour incubation 
with Aβo is sufficient to significantly increase the IP3R3 mRNA level in cultured mouse cortical neurons 
(Figure 5). 
How an increased ER-mitochondria coupling will ultimately cause pathological alterations at different levels 
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such as energy metabolism, lipid synthesis, mitochondria remodelling and apoptotic signalling has yet to be 
fully investigated.  
  
 
5. THE LYSOSOMAL CHANNELS 
A growing body of evidence has linked failure of the autophagic pathway to multiple outcomes in 
neurodegenerative disease. In AD, lysosomal Ca2+ storage/release defects accelerate amyloidogenesis, neuritic 
dystrophy and apoptosis. It is well known that vesicular Ca2+ is required for efficient vesicle fusion including 
lysosomal vesicles [118][119]. Lysosomal Ca2+ defects have been reported in PSEN−/− cells and neurons, thus 
suggesting an additional route through which PS dysfunctions impair cellular proteostasis and autophagic 
fluxes. Nixon and coworkers have shown that PS1 deficiency causes a primary defect in V-ATPase that 
determines lysosomal alkalinization [120]. Furthermore, the same authors have suggested that anomalous 
alkalinization causes hyperactivation of the transient receptor potential mucolipin-1 (TRPML1) channels 
located in the lysosomal membrane, thus inducing both organelle Ca2+ depletion and cytosolic Ca2+ overload 
[121]. Whereas in PSEN-DKO MEFs and PSEN1−/− hippocampal neurons defects in lysosomal Ca2+ content 
and fusion were fully confirmed, defective V-ATPase and lysosomal alkalinization were not reported [122]. 
How lysosomal Ca2+ depletion contributes to AD neuronal dysfunction and death is yet to be fully elucidated. 
Unfortunately, obtaining reliable measurements of Ca2+ dynamics inside acidic vesicles is still an unsolved 
challenge. Regarding AD mouse models based on PS2-N141I, we did not observe any significant effects of 
mutant PS2 on acidic Ca2+ pools: the combined use of ionomycin to release neutral stores, followed by 
monensin to collapse the proton gradient of acidic vesicles and allow ionomycin to release their Ca2+ content, 
demonstrated that the acidic pools of PS2-N141I expressing neurons have the same Ca2+ content of neurons 
from control mice [99]. Notwithstanding, small pH differences in acidic pools cannot be detect by this indirect 
approach. 
 
6. CONCLUDING REMARKS 
The brain consists of a vast array of interconnected neuronal and astrocytic cells. As such, the aforementioned 
intracellular Ca2+ dysregulations, when spread across different cell types and brain areas, can have a prominent 
effect on overall brain performance. Recent technical advances in Ca2+ imaging at the in vivo level, together 
with a deeper knowledge about the role of the different cell populations, have enabled us to look at the brain 
as a whole, spotting the effects of the subtle intracellular defects at the network level [123]. We also reported 
an increased susceptibility to a pro-epileptogenic protocol employing picrotoxin in acute slices of two-week 
old AD transgenic mice based on mutant PS2 [99], therefore highlighting the possibility that hyper-excitability 
and hyper-synchronicity are early network deficits that precede amyloid deposition [124]. Other works, 
focusing their attention on the astrocytic network of the APPswe/PS1DE9 AD mice and imaging Ca2+ waves 
in vivo, have shown that at 4-5 months of age astrocytes display an elevated resting Ca2+ level independent of 
plaque proximity. Nonetheless, spontaneous intracellular Ca2+ waves were observed in astrocytes close to 
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plaques, while they were able to spread over a distance of at least 200 µm [125]. The same authors found that 
neurons in close vicinity of Ab plaques are characterized by an increased activity driven by Ca2+ 
dyshomeostasis and affecting both structure and function that leads to a final disruption of the neuronal 
network [126]. In the frontal cortex of APP23xPS45 mice, hyperactive neurons were found in proximity of 
plaques but without a direct contact with them, suggesting a halo effect of soluble intermediates [127]. Indeed, 
the same authors demonstrated a massive increase in overall hippocampal activity and an altered ratio between 
hyperactive and hypoactive hippocampal neurons in young APP23xPS45 mice in the absence of plaques, thus 
concluding that neuronal hyperactivity is an early neuronal dysfunction of AD mouse models [128]. The 
noxious stimulus is likely represented by Abo such as dimers, trimers and higher order oligomers, species that 
exist before plaque formation and to whom plaques, once formed, represent a reservoir. In fact, local 
application of soluble Abo in the form of synthetic dimers mimicked hyperactivity of CA1 neurons in wild-
type mice in vivo [128]. However, these works do not distinguish the role of excitatory pyramidal neurons and 
inhibitory interneurons, an issue of profound importance when it comes to specific circuitry functionality. It is 
worth noting that AD patients show a 5- to 10-fold increased probability of experiencing epileptic seizures, 
which correlate with the progression of the cognitive decline [129][130]. The degree of neuronal activity might 
influence the level of Ab plaques deposition: it has recently been reported that cortical areas associated with 
elevated basal activity are more prone to develop amyloid deposits, and that the active unilateral vibrissae 
hyper-stimulation causes an increased plaque burden in the controlateral barrel cortex [131]. 
Increased neuronal hyper-excitability was observed in hippocampal slices not only from PS2APP mice but 
also from single mutant PS2 mice, i.e., with an extremely low level of Ab-load. Our data suggest that either a 
few pg/mg of wet tissue of Ab42 are sufficient to eliciting neuronal hyperactivity or that the ER Ca2+ defects 
themselves, due to the mutant PS2, are the initiating cause of altered network activity [99]. Curiously ER Ca2+ 
defects also characterize human fibroblasts obtained from FAD PS2-T122R twin patients, one of the two in 
the total absence of cognitive decline [7]. Taken together, these findings indicate that Ca2+ dysregulation, 
particularly at the store level, occurs precociously, likely accelerating the disease progression and could be 
instrumental to find early biomarkers of the disease onset. 
At the brain network level, the concerted activity of excitatory and inhibitory neurons originates signals 
oscillating in different frequency domains. The correct storage and retrieval of memories in the hippocampus 
strongly relies on this rhythmic activity, which is most prominently featured by the so-called theta (4-12 Hz) 
and gamma (25-100 Hz) oscillations. Theta and gamma rhythms can interact in a way that is known as cross-
frequency coupling, where the phase of the theta oscillation influences the amplitude of gamma wave. This 
synchronicity mechanism underlies the formation of the working memory, a functionality that is severely 
impaired in the AD patient [132][133]. These aspects of brain activity can be measured using a variety of 
methods, even on human subjects, but, in spite of their relevance, very little work has been carried out on this 
topic. It has recently been reported that, prior to plaque deposition, APP23 mice display a deeply altered 
rhythmic pattern, with an overall increased burst activity, met by a decreased theta rhythm power, an increased 
gamma component and an impaired cross-frequency coupling [134]. Both the balance between the two rhythms 
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and their coupling were influenced by riluzole, that blocks voltage-gated sodium channels, and MK-801, a 
NMDA receptor blocker, thus highlighting the importance of the activity-evoked Ca2+ signal [134]. Taken 
together, these results suggest how intracellular events linked to Ca2+ dysregulation, which affect neurons as 
well as other cell types in the brain, can ultimately lead to a diffuse dyshomeostasis on different activities, 
causing structural and functional damages that eventually result in brain dysfunction and cognitive decline. 
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FIGURE LEGENDS: 
 
FIGURE 1. Ab aggregation pathways. Ab42 can aggregate following different pathways that lead to 
different, albeit coexisting, products [121]. The left side shows a trimer-based aggregation process resulting in 
soluble aggregates of Low and High Molecular Weight (Abo) that are responsible for a vast array of cellular 
effects [122]. The right side shows the pathway leading to the formation of insoluble fibrils. Both pathway 
eventually can lead to plaques. Modified from [135]. 
FIGURE 2. Synaptic Abo targets. Abo impair the functionality of several targets localized at the synaptic 
level. We have here reviewed some of the major pathways involving Ca2+ dynamics, among which: 
metabotropic glutamate receptor (mGluR), store-operated Ca2+ channel (SOCC), cellular prion protein (PrPC), 
N-methyl-D-aspartate ionotropic glutamate receptor (NMDAR), nicotinic acetylcholine receptor (a7-nAChR), 
voltage-operated Ca2+ channel (VOCC). Other targets less directly involved on Ca2+ homeostasis such as the 
neuroligin-1 (NL-1) adhesion molecule and the low affinity Nerve Growth Factor receptor (p75), have not 
been included but see refs [123]. Only receptors located at the postsynaptic site are here highlighted; however, 
also targets at the presynaptic site should be considered to fully explain Abo toxicity. Modified from [136]. 
FIGURE 3. Preparation of synthetic Ab(1-42) monomers and oligomers. Human synthetic dry powdered 
Ab(1-42) (Anaspec, Fremont, CA, USA) is dissolved in 1,1,1,3,3,3-hexaflouro-2-isopropanol (HFIP) at room 
temperature (RT) for 1 hour to final concentration of 200 µM and stored as 10-20 µl aliquots at -80˚C until 
use. Aβ42o and Aβ42m are prepared according to the following procedure: aliquots are spun for 10 minutes 
(13,000 rpm, 5 min, 4oC) and then the HFIP is carefully removed by air fluxing with a pipette for several times 
and allowed to dry for about 10 minutes. The dried HFIP film is dissolved in DMSO (500 µM) and then diluted 
(50 µM) in double distilled water. When used immediately, the stock solution contained mainly monomers 
and low molecular weight (LMW) oligomers (6-17 kDa) whereas when left at RT for 48-72 hours it also 
contained high molecular weight (HMW) oligomers (50-100 kDa) that disappeared upon boiling [124] as 
shown from the Western blot on the right side. Since no quantification of HMW oligomers is carried out, the 
level of oligomers in the mixture is expressed as the equivalent concentration of monomers. Cells are routinely 
exposed to either Aβ42m or Aβ42o (0.5 µM) by adding 5 µL of the stock solution (50 µM, 10% DMSO) to 
0.5 mL of the bathing medium. Before cell treatment, the Aβ42 stock solution was spun (13,000 rpm, 10 min) 
and immediately used. Preparations are tested by transmission electron microscopy (TEM). Images are 
acquired on a Tecnai 12 microscope (FEI, Hillsboro, Oregon, USA) operating at 100kV. The stock Ab42 
solution (50 µM) of either oligomers or monomers is diluted 5 times in bi-distilled water, and 20 µl samples 
are placed on Formvar/carbon-coated nickel grids and blotted off after 2 minutes. Samples are negatively 
stained with uranyl acetate and observed at 90,000X magnifications. Ab42o particle diameter mainly ranges 
from 5 to 15 nm, consistent with a HMW oligomer population; Ab42m and LMW aggregates are not revealed 
by TEM [125]. 
FIGURE 4. Characterization of Abo by Western blot. Oligomeric preparations are separated by gel 
electrophoresis using a tris-tricine 4-10-16% polyacrilamide gel. Aβ42o are diluted in loading sample buffer 
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(LSB; in mM: 50 Tris, 50 tricine, 2% SDS, 12% glycerol, 80 dithiothreitol, pH 8.25 at RT) at the final 
concentration of 20 ng/µl. Samples (200-400 ng) were loaded in LSB on a 4-10-16% (w/v) Tris-Tricine 
discontinous gel in Tris-Tricine buffer with or without a boiling step (95°C, 10 min). Nitrocellulose membranes 
are saturated 1 hour at RT with a blocking solution containing 5% (w/v) non-fat dry milk (BioRad) in PBS 
plus Tween-20 [PBS-T; in mM: 136.89 NaCl, 6.7 KCl, 20 Na2HPO4, 3.67 KH2PO4, 0.1% (w/v) Tween-20, pH 
7.4], washed twice with PBS-T (10 min) and incubated 24 hours at 4°C with the primary antibody (6E10, 
Covance). The sample composition at 96 hours does not differ from that at 48 hours and it comprises monomers, 
dimers, trimers, tetramers and HMW oligomers, which are disrupted, alongside with the majority of tetramers 
and trimers, upon a 10-minute 95°C boiling procedure. See the enlarged monomer and dimer immuno-band in 
the boiled sample.  
FIGURE 5. Quantitative reverse-transcription polymerase chain reaction (qPCR). Cortical neuronal 
cultures at DIV 11-13, seeded in 12-well culture vessels are washed twice with mKRB and then incubated for 
1 h at 37oC with Aβ42o (0.5 µM) or vehicle (0.1% DMSO) [30]. Total RNA was extracted using the 
NucleoSpin RNA purification kit (Macherey-Nagel) and then quantified with NanoDrop 2000 (Thermo 
Scientific). For each sample, 500 ng of total RNA were reverse-transcribed into cDNA using the SuperScript 
II Reverse Transcriptase (Invitrogen) following the manufacturer’s instructions. PCR amplification was 
performed in an iQ5 Thermal Cycler (BioRad), using SYBR Green Supermix (BioRad) as reagent. For each 
cDNA, the efficiency of the reaction was estimated with a standard curve by using the cDNA reverse transcript 
from mouse brain. The transcript of Hypoxantine phosphoribosyl-transferase 1 (HPRT1) was used as internal 
control. The following primers (Invitrogen) were used: 
RyR2: 5’-GGCTTGCTCCAGATGAAACT-3 and 5’-CTTCGATCCGGTGCCTAAC-3’; 
RyR3:  5’-CAAACTGCCCTCCCTAAACA-3’ and 5’-AAACACGGTCCAAGAACAGC-3’; 
IP3R isoform 1: FW: 5’-CTCATGGACTGATTATGGACAGGAC-3’  
and 5’-GCAGGTCAGCAAAGAACTTATAGCC-3’; 
IP3R- 3: 5’-ATAAGAAGGAGAGACCCTCGG-3’ and 5’-CCACACATCTTGTTCAGCCT-3’; 
HPRT1: 5’- CTACAGAGTGCCTGACCT-3’ and 5’-TCGTAGATCCCTCCGCATAC-3’.  
Quantification followed the method of DCt comparison. Data are expressed as percentage ratio change 
relative to the HPRT1 transcript (mean ± SEM, n = number of wells). 
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